Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

897
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
897
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Vaccinations01:51

Vaccinations

51.0K
Overview
51.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Development of Immunocompetence01:22

Development of Immunocompetence

718
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
718
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study.

Arthritis research & therapy·2026
Same author

Can Phagocytosis, Neutrophil Extracellular Traps, and IFN-α Production in Systemic Lupus Erythematosus Be Simultaneously Modulated? A Pharmacological Perspective.

International journal of molecular sciences·2026
Same author

INH14, a Small-Molecule Urea Derivative, Inhibits the IKKα/β-Dependent TLR Inflammatory Response.

Chembiochem : a European journal of chemical biology·2018
Same journal

Actin scaffolds as organizers of presynaptic function, assembly and plasticity across species.

Biological chemistry·2026
Same journal

Neuronal membrane organization by the submembranous spectrin-ankyrin scaffold: evolution, specialization and disease.

Biological chemistry·2026
Same journal

Golgi-associated membrane scaffolds: roles in health and disease.

Biological chemistry·2026
Same journal

Mechanistic insights on spatiotemporal control of Ras-signaling.

Biological chemistry·2026
Same journal

Cysteine cathepsin proteases in apicomplexan parasites.

Biological chemistry·2026
Same journal

Electron donating and withdrawing groups affect the antioxidant activity of 4'-aminochalcones on gentamicin-induced kidney cell injury.

Biological chemistry·2026
See all related articles

Related Experiment Video

Updated: Jan 2, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Developments in anticancer vaccination: budding new adjuvants.

Sandra Santos-Sierra1

  • 1Section of Biochemical Pharmacology, Medical University of Innsbruck, A-6020 Innsbruck, Austria.

Biological Chemistry
|November 30, 2019
PubMed
Summary
This summary is machine-generated.

Synthetic Toll-like receptor (TLR) agonists show promise as adjuvants in cancer vaccination. These compounds enhance dendritic cell function, boosting adaptive immune responses crucial for tumor cell detection and killing.

Keywords:
Toll-like receptoradjuvantagonistcancer vaccination

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.1K

Related Experiment Videos

Last Updated: Jan 2, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.1K

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • The immune system's capacity to combat cancer is limited, requiring a balance between tumor rejection and immunosuppression.
  • Tumor microenvironments create protective barriers, and cancer cells develop mutations for immune evasion.
  • Effective cancer therapeutic vaccination necessitates robust activation of adaptive immune cells like CD4+ and CD8+ T-cells.

Purpose of the Study:

  • To review recent advancements in synthetic Toll-like receptor (TLR) agonists.
  • To explore the adjuvant potential of these TLR agonists in anti-cancer vaccination strategies.

Main Methods:

  • Literature review focusing on synthetic TLR agonists.
  • Analysis of their role in enhancing dendritic cell (DC) function.
  • Evaluation of their impact on T-cell priming for anti-cancer immunity.

Main Results:

  • Synthetic TLR agonists are emerging as effective immune adjuvants in cancer vaccination.
  • They improve dendritic cell maturation and antigen presentation capabilities.
  • Clinical studies show encouraging results with TLR agonists replacing traditional microbial adjuvants.

Conclusions:

  • Synthetic TLR agonists represent a significant advancement in cancer vaccine adjuvant development.
  • Their ability to potentiate anti-tumor adaptive immunity offers a promising therapeutic avenue.
  • Further research and clinical application of TLR agonists are warranted for improved cancer treatment outcomes.